A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
What is the purpose of this trial?
The main purpose of this study is to examine the safety and tolerability of CDX-1401 when given in combination with an immune stimulant (resiquimod) to patients with advanced cancers that are known to express the NY-ESO-1 protein.
- 18 Years - N/A
- Celldex Therapeutics
- September 2009
- Last Updated:
- February 2, 2015
- Study HIC#:
Clinicaltrials.gov ID: NCT00948961